Establishment and application of drug use evaluation criteria of argatroban

Published on Feb. 29, 2024Total Views: 784 times Total Downloads: 305 times Download Mobile

Author: DAI Hengfen ¹ ZHENG Caiyun ² LIU Yunchun ¹ ZHANG Hong ¹ LIU Maobai ³  ZHANG Jinghua ⁴

Affiliation: 1. Department of Pharmacy, Fuzhou First Hospital Affiliated with Fujian Medical University, Fuzhou 350009, China 2. Department of Clinical Pharmacy, Affiliated Fuqing Hospital of Fujian Medical University, Fuzhou 350300, China 3. Department of Pharmacy, Union Hospital Affiliated to Fujian Medical University, Fuzhou 350001, China 4. Department of Pharmacy, Fujian Maternity and Children Health Care Hospital, Fuzhou 350005, China

Keywords: Argatroban Drug use evaluation criteria Expert consultation method Rational drug use

DOI: 10.12173/j.issn.1005-0698.202312013

Reference: DAI Hengfen, ZHENG Caiyun, LIU Yunchun, ZHANG Hong, LIU Maobai,ZHANG Jinghua.Establishment and application of drug use evaluation criteria of argatroban[J].Yaowu Liuxingbingxue Zazhi,2024, 33(2):121-127.DOI: 10.12173/j.issn.1005-0698.202312013.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Objective To establish the argatroban drug use evaluation (DUE) criteria and provide reference for the rational use of argatroban in clinical practice.

Methods Based on the domestic and foreign drug instructions of argatroban, referring to relevant guidelines and literature, the DUE standard rules were established by expert consultation. Using the established standard rules, the medical records of argatroban in the Fuzhou First Hospital Affiliated with Fujian Medical University from August 2020 to August 2022 were evaluated for the rationality of medication.

Results A total of 368 medical records were included, the rational rate of drug use was 48.64%, and the irrational drug use was mainly without indications (46.19%) and inappropriate combination of drugs (4.35%).

Conclusion The rational rate of argatroban clinical use in the hospital is not high, and the problems mainly include off-indication drug use and unreasonable combination drug use. Through the establishment and clinical application of DUE standard rules, the clinical use of argatroban can be further standardized and the ability of rational drug use can be improved.

Full-text

Please download the PDF version to read the full text: download

References

1.中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志, 2018, 51(9): 666-682. DOI: 10.3760/cma.j.issn.1006-7876.2018.09.004.

2.Escolar G, Bozzo J, Maragall S. Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions[J]. Drugs Today (Barc), 2006, 42(4): 223-236. DOI: 10.1358/dot.2006.42.4.953588.

3.陈玉萍, 陶晓勇, 许胜杰, 等. 阿加曲班抗凝治疗后循环穿支动脉急性脑梗死疗效及安全性评价[J].中华老年心脑血管病杂志, 2022, 24(6): 611-613. [Chen YP, Tao XY, Xu SJ, et al. Efficacy and safety of agattriban in the treatment of posterior circulatory perforator artery acute cerebral infarction[J]. Chinese Journal of Geriatric Cardio-cerebrovascular Disease, 2022, 24(6): 611-613]. DOI: 10.3969/j.issn.1009-0126.2022.06.014.

4.董恒进，陈洁. 临床药物利用评价[J]. 中华医院管理杂志 , 1998, 14(8): 10-12. [Dong HJ, Chen J. Evaluation of clinical drug utilization[J]. Chinese Journal of Hospital Administration, 1998, 14(8): 10-12.] DOI: 10.3760/cma. j.issn.1000-6672.1998.08.104.

5.Yeh RW, Jang IK. Argatroban: update[J]. Am Heart J, 2006，151(6): 1131-1138. DOI: 10.1016/j.ahj.2005.09.002.

6.Liu S, Liu P, Wang P, et al. Argatroban increased the basal vein drainage and improved outcomes in acute paraventricular ischemic stroke patients[J]. Med Sci Monit, 2020, 26: e924593. DOI: 10.12659/MSM.924593.

7.脑卒中规范治疗专家组. 阿加曲班治疗急性缺血性脑卒中的应用建议[J]. 中华老年心脑血管病杂志, 2010, 12(9): 785-788. DOI: 10.3969/j.issn.1009-0126. 2010.09.006.

8.北京神经科学学会血管神经病学专业委员会, 阿加曲班治疗急性缺血性卒中中国专家共识组. 阿加曲班治疗急性缺血性卒中中国专家共识2021[J].中国卒中杂志, 2021, 16(9): 946-953. DOI: 10.3969/j.issn.1673- 5765.2021.09.012.

9.Jeske WP, Fareed J, Hoppensteadt DA, et al. Pharmacology of argatroban[J]. Expert Rev Hematol, 2010, 3(5): 527-539. DOI: 10.1586/ehm.10.53.

10.国家药品不良反应监测中心. 药品不良反应报告和监测工作手册[EB/ OL]. (2012-1l-01) [2023-02-20]. http://111.202.232.186/CDR/ help/index/index.html.

11.朱珠,施爱明,沈珠,等. 阿加曲班注射液用药合理性分析[J]. 中国现代应用药学, 2020, 37(8): 995-998. [Zhu Z, Shi AM, Shen Z, et al. Analysis of rationality of agatuban injection[J]. Chinese Journal of Modern Applied Pharmacy, 2020, 37(8): 995-998.] DOI: 10.13748/j.cnki.issn1007-7693.2020.08.020.

12.Keyl C, Zimmer E, Bek MJ, et al. Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia[J]. Thromb Haemost, 2016, 115(6): 1081-1089. DOI: 10.1160 / th15-11-0847.

13.中国微循环学会周围血管疾病专业委员会.静脉血栓栓塞症合并慢性肾脏疾病的抗凝治疗微循环专家共识 [J].血管与腔内血管外科杂志, 2021, 7(1): 1-13. DOI: 10.19418/j.cnki.issn2096-0646.2021.01.01.

14.刘晓辉,宋景春,张进华, 等.中国抗血栓药物相关出血诊疗规范专家共识[J]. 解放军医学杂志, 2022, 47(12): 1169-1179. [Liu XH, Song JC, Zhang JH, et al. Expert consensus on the diagnosis and treatment norms of antithrombotic medicine-related bleeding in China[J]. Medical Journal of Chinese People's Liberation Army, 2022, 47(12): 1169-1179.] DOI: 10.11855/j.issn.0577-7402.2022.12.1169.